Background:

Approximately 30,000 men die from advanced PCa annually. The prognosis of this disease stresses a need for novel therapeutic and clinical strategies.

Methods:

We analyzed targeted genes and proteins in 141 patient specimens using IHC (for as many as 29 different biomarkers), FISH for EGFR, ALK, c-Myc, Her2neu and TOP2A, sequencing for BRAF, c-ckit, EGFR, KRAS, and PIK3CA, and RNA expression microarray. Therapeutic associations from the published literature were then assigned based on the differentially expressed biomarkers. Due to amount of tumor tissue present in the specimen, physician test requests and other factors, the number of biomarkers interrogated varied from case to case.